Form 4: Kymera Therapeutics Director Acquires 16,000 Stock Options

Director Gorjan Hrustanovic acquired 16,000 stock options in Kymera Therapeutics, vesting fully by June 18, 2025, or the next annual meeting.

Summary

• Gorjan Hrustanovic, a director of Kymera Therapeutics, acquired 16,000 stock options on June 18, 2024.
• The exercise price of these options is $31.20.
• The options vest fully on the earlier of June 18, 2025, or the date of the next annual meeting of Kymera Therapeutics' stockholders.
• The options expire on June 17, 2034.
• Hrustanovic is a member of BVF Partners L.P. and will transfer any economic benefit from the sale of shares to BVF, disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative.

Positives

• A director increasing their stake in the company can be seen as a positive signal.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Management Comments

• The Reporting Person is a member of BVF Partners L.P. and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF.

Industry Context

This is a routine disclosure of stock option grants to a company director, common in the biotechnology industry to incentivize management and align their interests with shareholders.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment.

Key Dates